HNF4A and type 2 diabetes mellitus: In this work, we show that metformin, at clinically relevant concentrations, targets the TET3/HNF4α-P2 axis to inhibit HGP through the induction of let-7 using cell and mouse models of T2D and primary hepatocytes from obese humans.